Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination
Japanese Journal of Ophthalmology · 2024
DOI: 10.1007/s10384-024-01088-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, 2024. Verfasst von Yuko Maruyama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Corneal Injuries, Epithelium, Corneal, Brimonidine Tartrate, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To assess the effectiveness of switching from the concomitant use of brinzolamide 1% (BZM) and brimonidine 0.1% (BMD) to a BZM/BMD fixed-dose combination (BBFC) for the reduction of corneal epithelial damage. STUDY DESIGN: Retrospective cohort study. METHODS: This study involved 52 eyes of 52 glaucoma patients (26 women, 26 men; mean age: 67.0 ± 14.0 years) followed for more than 3 months after being switched from concomitant BZM and BMD to BBFC. Superficial punctate keratitis (SPK) was assessed by fluorescein staining according to the National Eye Institute classification, with the cornea divided into 5 areas: center, superior, nasal, temporal, and inferior. SPK density was graded as 0 (no SPK), 1 (separate SPK), 2 (moderately dense SPK), and 3 (high SPK with overlapping lesions). SPK scores and intraocular pressure (IOP) at pre switching to BBFC (pre-BBFC) and at 3-months post switching to BBFC (post-BBFC) were then compared using the Wilcoxon signed-rank test. RESULTS: At pre-BBFC and post-BBFC, respectively, mean IOP was 12.4 ± 2.5 and 12.4 ± 2.7 mmHg, thus illustrating no significant difference in IOP between pre and post switch (p = 0.924), and the mean SPK score for center, superior, nasal, temporal, and inferior was 0.06 ± 0.24, 0.04 ± 0.19, 0.52 ± 0.67, 0.15 ± 0.36, and 0.92 ± 0.74, and 0.04 ± 0.19, 0.02 ± 0.14, 0.37 ± 0.56, 0.04 ± 0.19, and 0.75 ± 0.62, thus clearly showing a significant reduction in SPK scores for the nasal, temporal, and inferior areas at post-BBFC compared to those at pre-BBFC (p < 0.05). CONCLUSION: Our findings reveal that compared with the concomitant use of BZM and BMD, BBFC is effective in reducing corneal epithelial damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-0841, Japan.
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-0841, Japan. yikeda@koto.kpu-m.ac.jp.
- Oike-Ikeda Eye Clinic, Kyoto, Japan. yikeda@koto.kpu-m.ac.jp.
- Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Ophthalmology, Baptist Eye Institute Nagaokakyo, Kyoto, Japan.
Zitieren
APA
Maruyama, Y., Ikeda, Y., Yoshii, K., Mori, K., Ueno, M., Kinoshita, S., & Sotozono, C. (2024). Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01088-w
Vancouver
Maruyama Y, Ikeda Y, Yoshii K, Mori K, Ueno M, Kinoshita S, et al. Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination. Japanese Journal of Ophthalmology. 2024. doi:10.1007/s10384-024-01088-w
BibTeX
@article{Maruyama2024,
author = {Maruyama, Yuko and Ikeda, Yoko and Yoshii, Kengo and Mori, Kazuhiko and Ueno, Morio and Kinoshita, Shigeru and Sotozono, Chie},
title = {Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination},
journal = {Japanese Journal of Ophthalmology},
year = {2024},
doi = {10.1007/s10384-024-01088-w}
}
EUVIMED